ALX Oncology Holdings Inc. (ALXO) News
Filter ALXO News Items
ALXO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALXO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ALXO News From Around the Web
Below are the latest news stories about ALX ONCOLOGY HOLDINGS INC that investors may wish to consider to help them evaluate ALXO as an investment opportunity.
3 US Penny Stocks With Market Caps Under $100M To WatchAs the U.S. stock market experiences fluctuations, with major indices showing slight gains and losses, investors are keeping a close eye on economic indicators that could influence interest rate decisions. Amidst these market dynamics, penny stocks continue to capture attention for their potential growth opportunities at lower price points. Although often associated with smaller or newer companies, these stocks can offer significant upside when backed by strong financials and solid fundamentals. |
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year. |
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer, Jason Lettmann, will deliver a company overview presentation on Wednesday, January 15, 2025, at 3:00 p.m. Pacific |
Top Midday DeclinersJefferies downgraded the shares of ALX Oncology (ALXO) to hold from buy while cutting its price targ |
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold'Shares of Alx Oncology (NASDAQ:ALXO) fell in pre-market trading Thursday after Jefferies downgraded the stock to "hold" rating from a "buy," citing concerns over the company's clinical trial results and the higher burden of proof for its flagship drug, evorpacept. Jefferies analysts noted that while ALX Oncology initially generated investor excitement with its Phase II interim results in gastric cancer, the complete dataset revealed weaker outcomes. Jefferies highlighted challenges in the ongoing trials for head and neck cancer, with early data showing only modest differentiation from existing treatments like Keytruda. |
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers SymposiumSOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will b |
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced that the company will host a virtual event on Tuesday, December 17, at 5:00 AM PST / |
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast CancerData from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast cancer who had received multiple HER2-targeted agents, including fam-trastuzumab deruxtecan-nxki (ENHERTU®)Combination therapy was well tolerated with a manageable safety profile consistent with prior experience with each investigational agentData contribute to growing evidence supporting evorpacept act |
3 US Penny Stocks With Market Caps Over $30M To ConsiderAs the U.S. stock market rally continues, with major indices like the Dow Jones Industrial Average and S&P 500 reaching new highs, investors are increasingly exploring diverse investment opportunities. While penny stocks may seem like a term from a bygone era, they remain relevant for those seeking affordable entry points into smaller or newer companies with growth potential. By focusing on financial strength and growth prospects, these investments can offer unique opportunities in today's... |
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that Jason Lettmann, the Company’s Chief Executive Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held in New York City from December 3-5, 20 |